Literature DB >> 24817339

Hodgkin lymphoma following adalimumab for the treatment of Crohn's disease in an adolescent.

Alexis A Rodriguez1, John Kerner, Sandra Luna-Fineman, Gerald J Berry.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24817339     DOI： 10.1007/s10620-014-3191-6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  8 in total

1.  Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study.

Authors:  C Romano; S Cucchiara; A Barabino; V Annese; C Sferlazzas
Journal:  World J Gastroenterol       Date:  2005-12-07       Impact factor: 5.742

Review 2.  Targeting survival pathways in lymphoma.

Authors:  Luca Paoluzzi; Owen A O'Connor
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

3.  Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.

Authors:  A Kandiel; A G Fraser; B I Korelitz; C Brensinger; J D Lewis
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

Review 4.  TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility.

Authors:  Remco van Horssen; Timo L M Ten Hagen; Alexander M M Eggermont
Journal:  Oncologist       Date:  2006-04

5.  Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease.

Authors:  Riad M Rahhal; Warren P Bishop
Journal:  Inflamm Bowel Dis       Date:  2008-12       Impact factor: 5.325

6.  Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation.

Authors:  Judith Offman; Gerhard Opelz; Bernd Doehler; David Cummins; Ozay Halil; Nicholas R Banner; Margaret M Burke; Dianne Sullivan; Peter Macpherson; Peter Karran
Journal:  Blood       Date:  2004-04-15       Impact factor: 22.113

Review 7.  Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review.

Authors:  Alex Gutierrez-Dalmau; Josep M Campistol
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.

Authors:  Corey A Siegel; Sadie M Marden; Sarah M Persing; Robin J Larson; Bruce E Sands
Journal:  Clin Gastroenterol Hepatol       Date:  2009-01-24       Impact factor: 11.382
  8 in total
  3 in total

Review 1.  Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders.

Authors:  Grace Y Lam; Brendan P Halloran; Anthea C Peters; Richard N Fedorak
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

2.  Hodgkin's Lymphoma in Crohn's Disease Treated with Infliximab.

Authors:  Diana Carvalho; Pedro Russo; Carlos Bernardes; Joana Saiote; Gonçalo Ramos; Luís Mascarenhas; Nuno Borges; Jaime Ramos
Journal:  GE Port J Gastroenterol       Date:  2017-09-06

3.  Primary cutaneous anaplastic large cell lymphoma in a patient receiving adalimumab.

Authors:  Chad J Hruska; Robert J Bertoli; Yorke D Young; Patrick H Burkhart; Paul B Googe
Journal:  JAAD Case Rep       Date:  2015-02-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.